Nosocomial infections caused by Acinetobacter species have been increasing in frequency over the past years [1] . These bacteria cause several types of nosocomial infections, such as bacteremia, pneumonia, meningitis, urinary tract, and surgical wound infections [1] . Nosocomial Acinetobacter baumannii infections have a high related mortality; the case fatality rate ranges between 19% and 44% in cases of bacteremia [2, 3] . In addition, ventilator-associated pneumonia in hospitalized patients that is caused by Acinetobacter species, among other etiologies, is associated with high mortality [4, 5] .
Acinetobacter meningitis is a severe nosocomial infection caused by A. baumannii and is associated with a mortality rate of20%-27% [6, 7] . Most of the reported cases have occurred in a neurosurgical setting and have been associated with indwelling ventriculostomytubes, CSF fistulae, or head trauma [6] [7] [8] [9] . Nosocomial acinetobacter meningitis has been caused by the intrathecal administration of contaminated methotrexate solution to children with leukemia, with a mortality of 37.5% [10] .
Most of the reported cases of acinetobacter meningitis have been treated with imipenem, leading to recovery in 11 of 13 cases (84.6%) [8, 9, 11, 12] . However, the extensive use of imipenem may induce the appearance of acinetobacter infections caused by strains resistant to imipenem [13, 14] , leaving few therapeutic options, especially for the management of CNS infections. This article describes the clinical features and the outcome of nosocomial A. baumannii meningitis treated with ampicillin/sulbactam.
Methods
We performed a retrospective clinical study to evaluate the outcome of eight cases of postneurosurgical meningitis caused by multiresistant A. baumannii during the period between January 1993 and December 1995.
All patients met the following inclusion criteria: (1) clinical signs of meningitis (fever, meningeal signs, low consciousness level); (2) pleocytosis, low glucose level, and elevated protein level in the CSF; (3) isolation of A. baumannii from CSF; and (4) treatment with ampicillin/sulbactam.
All CSF cultures were processed by the hospital laboratory with use of the Bactec NR860 system (Becton Dickinson, Cockeysville, MD). A. baumannii was identified by the MicroScan system (Baxter Health Care, West Sacramento, CA), the API 20 NE system (bieMerieux, Marcy l'Etoile, France), and temperature growth tests [15] . Susceptibility to antimicrobial agents was determined by the MicroScan system, with use ofthe Neg Breakpoint Combo Panel 21(Baxter Health Care), according to the norms established by the National Committee for Clinical Laboratory Standards [16] . Susceptibility to sulbactam was also determined by microdilution in MuellerHinton broth [16] .
Clinical cure was considered to be the disappearance of fever and meningeal signs, improvement of consciousness level (in cases of low consciousness directly related to meningitis), and remission of CSF alterations at the time the therapy was discontinued. Bacteriologic cure was defined as elimination of A. baumannii from CSF during therapy. Death was considered to be related to meningitis if it occurred during treatment for meningitis. A. baumannii meningitis was considered to be related to a CSF shunt if it appeared following placement of the CSF shunt, if the CSF at the time of placement was sterile, and if there were no other neurosurgical procedures in the period of time between the shunt placement and the onset of meningitis.
The results of analyses of continuous variables are expressed herein as mean ± SD.
Results
Eight patients (four men and four women) between 30 and 74 years of age were included. The most common underlying condition was intracerebral or subarachnoid hemorrhage (six cases) (table 1). All patients underwent surgical procedures, involving 3 craniotomies, 2 burr hole drillings, and 6 placements of external CSF shunts, which were in place for 3-17 days (10.5 ± 6.3 days) before onset of meningitis. The external CSF shunt was directly related to A. baumannii meningitis in five cases (83%). Four patients had CSF fistulae at the craniotomy and/or burr hole sites. One case had A. baumannii surgical wound infection prior to meningitis. Seven patients had been in the intensive care unit and seven had received antimicrobial treatment prior to onset of meningitis.
All the patients had fever (39.06 ± 0.69°C), neck stiffness or meningeal signs, and a low consciousness level (coma in six cases and stupor and somnolence in one case each). Five patients had nausea and/or vomiting and three suffered seizures. The neurological deficits and the headaches were difficult to evaluate because of the underlying conditions. Leukocytosis (18,817 ± 6,lOlIpL) with a polymorphonuclear predominance was noted in seven patients. In all CSF specimens, pleocytosis (4,383 ± 6,927 cells/ul.) with a polymorphonuclear predominance, an elevated protein level (415 ± 219 mg/dl.), and a low glucose level (14 ± 15 mg/dL) were noted.
In seven episodes, additional A. baumannii isolates were recovered from other samples (table 1). All A. baumannii isolates were susceptible to ampicillin!sulbactam (MIC,~8/4 p,glmL, per MicroScan system) and resistant to cefotaxime, ceftriaxone, ceftazidime, ureidopenicillins, ciprofloxacin, and gentamicin. Seven isolates were also resistant to imipenem. The microdilution MICs of sulbactam in two cases (cases 2 and 3) were 4 tLg/mL.
The dosages and the duration of treatment with ampicillin! sulbactam appear in table 1. Three patients also received intraventricular aminoglycosides. Three patients received dexamethasone (4 mg t.i.d.) for cerebral edema and/or anticonvulsant drugs (two received phenytoin and one received phenobarbital). All the ventriculoperitoneal or external CSF shunts were removed.
Two patients (25%) died of meningitis. Resolution of the symptoms and signs of meningitis and improvement of CSF findings on day 8 of treatment with ampicillin!sulbactam were noted in case 1; however, the CSF culture remained positive and the patient was switched to imipenem therapy for 14 more days. There were no side effects with the ampicillin!sulbactam treatment. Furthermore, there were neither recurrences nor superinfections.
Discussion
The cases of acinetobacter meningitis in this study were related to head trauma or neurosurgical procedures, including placement of external ventricular devices (present for > 5 days), factors which have previously been associated with this infection [6] [7] [8] [9] 17] . The excessive administration of antimicrobial agents to neurosurgical patients may facilitate the appearance of acinetobacter meningitis [6, 9] , as probably occurred in seven of the cases in the present study.
Nosocomial A. baumannii infections have a high related mortality, with a case fatality rate of 20%-27% for acinetobacter meningitis [6, 7] . The mortality is related to inappropiate treatment of bacteremias due to A. baumannii [3] , a finding which stresses the importance of correct empirical treatment.
Many nosocomial A. baumannii strains are resistant to a wide variety of antimicrobial agents. Imipenem, tetracycline, ampicillin!sulbactam, polymyxin B, and (according to some studies) ceftazidime and ciprofloxacin are among the more active antimicrobial agents against A. baumannii [3, [18] [19] [20] . However, antimicrobial susceptibility patterns may change from hospital to hospital. Thus, the use of imipenem for acinetobacter infections caused by strains that are only imipenemsusceptible may induce the appearance of imipenem-resistant acinetobacter infections.
Urban et al. [13] referred to an outbreak of acinetobacter infections that necessitated widespread use of ceftazidime and later the use of imipenem. Subsequently, they observed Acinetobacter strains resistant to all antimicrobial agents tested, including imipenem, ceftazidime, and amikacin [13] . We have observed a steady increase in the incidence of multiresistant A. baumannii infections in our hospital, including those resistant to imipenem, after extensive use of this antimicrobial agent. For instance, only 43%, 26%, and 38% of A. baumannii isolates from the same building ofthe hospital were susceptible to imipenem in 1993, 1994, and 1995, respectively.
In the treatment of imipenem-resistant acinetobacter infections, ampicillin!sulbactam has been useful for patients with respiratory tract infections and bacteremia [13] . Ampicillin! sulbactam was also useful in the treatment of uncomplicated urinary tract infections [21] . There are few clinical data on the treatment of meningitis with ampicillin!sulbactam. These (3-1actam drugs have been effective in the treatment of bacterial meningitis caused by Haemophilus infiuenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Staphylococcus species in infants, children, and adults [22] [23] [24] .
Only one patient with acinetobacter posttraumatic meningitis was treated and cured with ampicillin!sulbactam [22] . Sulbactam penetrates into the CSF of patients with bacterial meningitis in a pattern similar to that of ampicillin [23] . One gram of sulbactam administered intravenously achieved CSF concentrations as high as 32% of serum concentrations (8.5 }1g/mL) in patients with meningitis [25] but < 1% of those in patients without meningitis [26] .
There are data indicating thatsulbactam is responsible for the bactericidal effect of ampicillin/sulbactam on Acinetobacter species. Sulbactam was more active than ceftazidime and clavulanate on Acinetobacter calcoaceticus, both in vitro and in vivo, in mice models of intraperitoneal infection [27] . In another study, of 20 Acinetobacter strains that were resistant to imipenem and most probably of clonal origin, the MIC 90 of sulbactam was~4 }1g/mL and the MIC 90 of ampicillin!sulbactam was~8/4 }1g/mL, while the MIC 90 of ampicillin was> 128 }1g/mL [13] .
The mortality rate in our study (25%) was similar to those previously reported with regard to acinetobacter meningitis [6, 7] and slightly higher than the mortality of 15.4% among 13 cases treated with imipenem [8, 9, 11, 12] . Seven of the patients in the present study had another acinetobacter infection, such as tracheobronchitis or pneumonia and bacteremia, which are associated with high mortality [3] [4] [5] . Eradication of Acinetobacter species from the CSF in shunt-associated meningitis required complete removal of ventricular devices plus administration of bactericidal antibiotics. In this study, all external or ventriculoperitoneal CSF shunts were removed. There were neither recurrences nor superinfections.
In conclusion, the results of this study suggest that administration of ampicillin!sulbactam may be an effective therapy for meningitis caused by A. baumanii resistant to imipenem and other (3-lactam drugs.
